Early, Very High-Titre Convalescent Plasma Therapy in Clinically Vulnerable Individuals with Mild COVID-19: An International, Randomised, Open-Label Trial {Pre-print} [Nov 9, 2024] Hoffmann et al. @TheLancet papers.ssrn.com/sol3/papers.... #NCT05271929 #COVID19CP #COVID19

Early, Very High-Titre Convalescent Plasma Therapy in Clinically Vulnerable Individuals with Mild COVID-19: An International, Randomised, Open-Label Trial Background: COVID-19 convalescent plasma (CCP) is a treatment option for COVID-19. This study investigated the safety and efficacy of early, very high-titre CCP

Early, Very High-Titre Convalescent Plasma Therapy in Clinically Vulnerable Individuals with Mild COVID-19: An International, Randomised, Open-Label Trial {Pre-print} [Nov 9, 2024] Hoffmann et al. The Lancet papers.ssrn.com/sol3/papers.... #NCT05271929 #COVID19CP #COVID19